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Introduction 
 
G-protein-coupled receptors 
 
G protein-coupled receptors (GPCRs) are proteins very highly conserved through 
evolution and thereby expressed in nearly all organisms ranging from yeast to human 
beings. GPCRs are encoded by almost 1% of the human genome and targets more than 
40% of the drugs nowadays used in therapeutics (Ma and Zemmel, 2002). The chemical 
diversity found among the endogenous ligands is exceptional. Thus they include 
biogenic amines, peptides, glycoproteins, lipids, nucleotides, ions, and proteases. 
Moreover, the sensation of exogenous stimuli, such as light, odors, and taste, is mainly 
mediated via this class of receptors (Kolakowski, 1994; Hoon et al., 1999). 
 
According to a commonly used classification scheme (Horn et al., 2003), most GPCRs 
are grouped in classes A–E. Class A is the most widespread and contains rhodopsin-like 
GPCRs, class B contains the secretin-like GPCRs, while class C the metabotropic 
glutamate/pheromone receptors. These are the main classes of receptors in animals. The 
rhodopsin family is by far the largest and most diverse of these families, and members 
are characterized by conserved sequence motifs that imply shared structural features and 
activation mechanisms. The link between an activated GPCR and the cell physiological 
responses is a heterotrimeric G-protein (αβγ) whithin the interior of the cell that 
interacts with the activated receptor. Four families of G-proteins are defined in the 
literature, i.e. Gαi/o, Gαq/11, Gαs and Gα12/13, (Elefsinioti et al., 2004), based on 
sequence similarity among different α subunits that are the main determinants of G-
protein coupling specificity. 
 
Despite their molecular and functional diversity, all GPCRs share a similar structure 
consisting of seven transmembrane domains linked by alternating intracellular and 
extracellular loops, presenting the amino terminus located on the extracellular side and 
the carboxy terminus in the intracellular side (Rosenbaum et al., 2009). Extracellular 
domains, which vary among the different classes of GPCRs, contribute to ligand 
recognition and binding, whereas coupling to G proteins is determined mainly by 
interactions with intracellular domains (Kristiansen, 2004). When a GPCR agonist binds 
to the extracellular domain it induces a change in the conformation of the receptor. This, 
in turn, leads to coupling to and activation of one or more G proteins inside the cell.  
 
GPCRs act at the heterotrimeric G proteins as guanine-nucleotide exchange factors; 
thus, the activated receptor induces a conformational change in the associated G protein 
α-subunit leading to release of GDP followed by binding of GTP (Bourne et al., 1991). 
Subsequently, the GTP-bound form of the α-subunit dissociates from the receptor as 
well as from the stable βγ-dimer. Both the GTP-bound α-subunit and the released βγ-
dimer might modulate several cellular signaling pathways. These include, among others, 
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stimulation or inhibition of adenylate cyclases and activation of phospholipases, as well 
as regulation of potassium and calcium channel activity (Hamm et al., 1998). 
 
To date, four opioid receptors have been cloned: μ-, δ-, κ-, and nociceptin/orphanin FQ 
receptors (Waldhoer et al., 2004). The opioid family assignment is based on sequence 
and functional homology, and conservation of exon structure and gene regulation (Law 
et al., 2004). The μ-, δ-, and κ-opioid receptors are about 60% identical to each other, 
with the greatest identity found in the transmembrane domains (73–76%) and 
intracellular loops (86–100%). The greatest divergent areas were found in the N-
terminus (9–10%), extracellular loops (14–72%) and the C-terminus (14–20%) (Chen et 
al., 1993). 
 
Mu-Opioid Receptors 
 
Mu-opioid receptors (MOP) are members of GPCRs superfamily, and they mainly 
modulate the function of effector molecules, such as adenylate cyclase and protein 
kinases (Standifer and Pasternak, 1997). They are coupled primarily to G proteins of the 
Gi/Go family. Signaling from MOP receptors is rapidly regulated by a well-
characterized and highly conserved cascade of events involving receptor 
phosphorylation by G protein-coupled receptor kinases (GRKs) and subsequent β-
arrestin recruitment (Ferguson, 2001). These processes contribute directly to rapid 
GRK- and β-arrestin-mediated desensitization by facilitating the uncoupling of the 
receptor from its G protein.  
Following desensitization by GRKs and β-arrestin, opioid receptors are then rapidly 
endocytosed into intracellular compartments. This process occurs following even brief 
agonist exposure and independently of signal transduction (Arden et al., 1995). The 
speed and conservation of this process is ideal for modulating signaling from 
endogenous ligands, such as neurotransmitters, that are released in a pulsatile manner. 
Following their endocytosis, receptors can then be recycled back to the membrane, 
thereby restoring the functional complement of receptors, a process termed 
“resensitization.” In contrast, chronic exposure of MOP receptors to agonist, for 
example, during exogenous drug administration, can also lead to receptor 
desensitization/uncoupling.  
Receptors that have been desensitized and rapidly endocytosed are uniquely poised to 
make an important decision with substantial impact on future signal transduction. As 
mentioned above, following endocytosis receptors can be recycled thereby restoring the 
functional complement of receptors. Alternatively, receptors that have been 
endocytosed can be targeted for degradation, thereby decreasing the functional 
complement of receptors ultimately resulting in receptor downregulation. Although 
endocytosis and subsequent degradation of receptors are not the only means of 
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producing receptor downregulation, they can produce receptor downregulation rapidly, 
even following brief exposure to agonist (Tsao and von Zastrow, 2000).  
Endocytosis occurs by various mechanisms, which can be divided into those that are 
clathrin dependent and those that are clathrin independent (Conner and Schmid, 2003; 
Doherty and McMahon, 2009). In clathrin dependent endocytosis (CDE), the 
cytoplasmic domains of plasma membrane proteins are specifically recognized by 
adaptor proteins and packaged into clathrin-coated vesicles that are brought into the 
cell. CDE is facilitated by numerous accessory proteins, requires the GTPase dynamin 
for vesicle scission and has been widely studied (Conner and Schmid, 2003; Doherty 
and McMahon, 2009). Clathrin-independent endocytosis (CIE), in contrast, might 
occurs in many forms and has been less well studied. There are also specialized actin-
driven CIE pathways (Swanson, 2008), such as macropinocytosis and phagocytosis, and 
these might be stimulated forms of CIE (Donaldson et al., 2009). There seem to be 
several distinct mechanisms of CIE (Mayor and Pagano, 2007) that might reflect, to 
some extent, the different cell types and cargo molecules monitored. Caveolar 
endocytosis involves the caveolin coat, is dynamin dependent and is the mechanism that 
glycosphingolipids use for cell internalization (Mayor and Pagano, 2007). 
 
The role of endocytosis in modulating signaling from the receptor comprises both 
endocytic events (desensitization) and post-endocytic sorting events (resensitization or 
downregulation). 
 
Many GPCRs display a certain level of basal signaling activity and thus can activate G 
proteins in the absence of agonists, this process is known as constitutive activity. MOP 
receptors have also been shown to exhibit basal signaling activity in SH-SY5Y cells and 
in transfected HEK293 cells (Wang et al., 1994; Burford et al., 2000) and display more 
elevated constitutive activity following chronic exposure to morphine (Wang et al., 
1994). 
 
Morphine and other derivatives of this alkaloid compound are drugs widely known for 
its analgesic properties in clinical practice as well as by its consumption as recreational 
drugs. In the nervous system, MOP receptors drive the initial steps of both the positive 
effects of morphine, i.e. relief of intense pain, and its addictive effects.  
 
Morphine and other opioids remain the analgesics of choice for the treatment of chronic 
pain. However the major limitation to their long-term use is the development of 
physiological “tolerance,” a profound decrease in analgesic effects observed in most 
patients during prolonged drug administration. In addition to tolerance, physiological 
“dependence,” which results in the necessity for continued administration of increasing 
doses of drug to prevent the development of symptoms of opioid withdrawal, can ensue 
in some patients. Not all opioid drugs generate the same degree of tolerance and 
dependence in experimental animals when administered chronically at equi-effectives 
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analgesic doses, therefore this fact leads to the consideration that binding of these 
agonists to MOP receptor should produce different effects at the cellular and molecular 
level (Lopez-Gimenez and Milligan, 2010). Morphine is distinguished from other 
agonist drugs that bind and activate mu opioid receptors by its marked ability to 
generate tolerance and dependence when is used for prolonged treatments. Interestingly 
and in contrast to other alkaloid drugs, morphine is inefficient in promoting MOP 
receptor endocytosis. This peculiarity has generated a plethora of scientific debates and 
controversy (von Zastrow et al., 2003; Bailey and Connor, 2005; Koch and Hollt, 2008). 
 
Heterologous Expression Systems 
 
The development of recombinant cDNA methodology, combined with a wide range of 
molecular and cell biology techniques,  has made feasible the expression of particular 
genes of interest into a vast variety of host cells. Heterologous expression systems 
provide a cellular context in which properties of a given receptor may be studied in the 
absence of the native intricate background, alleviating the complexity due to the 
presence of multiple receptor sub-types and/or to coupling to more than one class of G-
proteins.  In most cases, heterologous expression allows the analysis of single receptor 
subtypes in a defined system, and in addition provides easy access to human receptors 
outside their native tissues.  
 
Particularly in our field of interest, such heterologous expression systems have been 
extremely useful to investigate pharmacological and molecular properties of each opioid 
receptor subtype when expressed individually. Furthermore, these experimental models 
allow the expression of genetically modified receptors in a way that facilitates their 
study, for example containing a short amino acid sequence as an epitope that is 
recognized specifically by an antibody. The use of such epitope-tagged receptors has 
provided means to employ biochemical techniques to facilitate the cellular and 
molecular studies of these GPCRs. 
 
In the present study we used the Flp-InTM T-RExTM as heterologous expression system 
in order to expressed our gene of interest, MOP receptor, in an inducible manner. 
Briefly, MOP receptor was sub-cloned into pcDNA5 vector and subsequently 
transfected into the Flp-In mammalian host cell line. 
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Parental Flp-In Hek293 cells contain the Flp Recombination Target site and expressed 
the Tet repressor (Fig. 1). After transfection, the pcDNA5 integrates at the Flp 
Recombination Target site and the Tet repressor protein binds to the Tet-Operon region 
of the integrated pcDNA5, wich controls the gene expression by repressing it. 
Doxycycline binds the Tet repressor after addition to the cells, releasing therefore the 
Tet operator and enabling MOP receptor expression. 
 
Fluorescent Proteins 
The discovery and development of fluorescent proteins from a wide variety of 
organisms has initiated a revolution in the study of cell biology by providing convenient 
markers for gene expression and protein targeting in living cells and organisms. The 
resulting fusion product can be used to localize previously uncharacterized proteins or 
to visualize and track known proteins to further understand cellular events. The use of 
fluorescent proteins as a minimally invasive tool for studying protein dynamics and 
function has been stimulated by the engineering of genetic variants with improved 
brightness, photostability and expression properties. Cells that express gene products 
tagged with fluorescent proteins can be imaged with low light intensities over many 
hours to provide useful information about changes in the steady-state distribution of a 
protein over time (Tsien, 1998). 
 
Figure 1. Schematic representation of Flp-InTM T-RExTM system. Tet repressor proteins bind to Tet 
Operon (TetO2) repressing the expression of MOP receptor. The addition of doxycicline binds Tet 
repressor proteins, releasing the tet operator and enabling MOP expression. Flp Recombination Target 
sites (FRT) are the sites for the insertation by homologous recombination of the construct.    
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Red Fluorescent Proteins 
The first coral-derived fluorescent protein to be extensively utilized was derived from 
Discosoma striata and is commonly referred to as DsRed. Maturation of DsRed 
fluorescence occurs slowly and proceeds through a time period when fluorescence 
emission is in the green region. Furthermore, DsRed is an obligate tetramer and can 
form large protein aggregates in living cells. Although these features are 
inconsequential for the use of DsRed as a reporter of gene expression, the usefulness of 
DsRed as an epitope tag is severely limited. A few of the problems with DsRed 
fluorescent proteins have been overcome through mutagenesis. The second-generation 
DsRed, known as DsRed2, contains several mutations at the peptide amino terminus 
that prevent formation of protein aggregates and reduce toxicity. In addition, the 
fluorophore maturation time is reduced with these modifications (Bevis and Glick, 
2002) 
mCherry is a red monomeric fluorescent protein derived from the tetrameric Discosoma 
protein DsRed. The mCherry coding sequence has been human codon-optimized to 
allow optimal expression in mammalian cells. mCherry matures very rapidly (t1/2=15 
min.), making it possible to see results very soon after the gene expression (Shaner et 
al., 2004). Is highly photostable and resistant to photobleaching, and as a monomeric 
fluorescent protein is often ideal for fusions as they tend to be the least disruptive to the 
function of the protein to which it is fused. Properties of mCherry fluorescent protein 
are shown in Table 1.  
Table 1. Compilation of properties of mCherry fluorescent protein. Along with the common 
name, the peak absorption and emission wavelengths (given in nanometers), molar extinction 
coefficient, quantum yield, relative brightness, and in vivo structural associations are listed. The 
computed brightness values were derived from the product of the molar extinction coefficient 
and quantum yield, divided by the value for EGFP. 
Protein 
(Acronym) 
Excitation 
Maximum 
(nm) 
Emission 
Maximum 
(nm) 
Molar 
Extinction 
Coefficient 
Quantum 
Yield 
in vivo 
Structure 
Relative 
Brightness 
(% of 
EGFP) 
mCherry 587 610 72,000 0.22 Monomer 
 
47 
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Objectives 
Taking into account the central role of MOP receptor in the different cellular signaling 
pathways and physiological effects promoted by morphine, the main objective of our 
research is the generation of an inducible heterologous expression system harboring 
MOP receptor to conduct further investigations on its molecular pharmacology. To meet 
this objective we set the following tasks: 
• Generation of a stable cell line expressing MOP-Cherry receptor in an inducible 
manner 
• Fluorescence microscopy studies 
• Pharmacological studies 
 
Materials and Methods 
Cell Culture 
Modified human embryonic kidney (Flp-In HEK293) cells were grown in Dulbecco's 
modified Eagle's medium (DMEM) (Invitrogen, Carlsbad, CA) supplemented with 10% 
fetal bovine serum (CLINOR), 10ml/L penicillin G/streptomycin (CLINOR), 1mg/ml 
Blasticidine (IBIAN Technologies) and 100mg/ml hygromicine (IBIAN Technologies). 
Cells were maintained at 37°C in a humidified environment containing 5% CO2. 
When indicated, cells were incubated with 500 µg/mL concanavalin A (Con A) 
(SIGMA), 100 ng/ml Pertusis toxin (PTX) (SIGMA), 10-5 M naloxone hydrochloride or 
naltrexone (SIGMA) or 80 µM dynasore monohydrate (SIGMA) for the different 
periods showed in results.  
 
Receptor Fusions with Fluorescent Proteins 
A human mu opioid (MOP) receptor C-terminally tagged with enhanced mCherry 
fluorescent protein (mCherry) was constructed by amplifying the sequence 
corresponding to the receptor by PCR primers containing a Hind III endonuclease site at 
the 5`end and a Not I endonuclease site at the 3`end removing in the process the stop 
codon. This PCR product was ligated to the fluorescent protein sequence amplified by 
PCR and containing the same endonuclease restriction site (NotI). The final product of 
this ligation corresponds to a single open reading frame encoding the receptor 
fluorescent protein fusion. MOP-Cherry was subcloned into the vector 
pcDNA5/FRT/TO (Invitrogen) for the subsequent generation of Flp-In T-REx HEK293 
cell line. 
 
Generation of Stable Flp-In T-REx HEK293 Cell Line 
To generate Flp-In T-REx HEK293 cell line able to express MOP-Cherry receptor in an 
inducible manner, cells were transfected with a mixture containing MOP-Cherry 
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receptor cDNA into pcDNA5/FRT/TO vector and pOG44 vector (1:9). DNA solution 
[1.5 µg] was mixed with 1mg/ml of Polyethylenimine (PEI) reagent (Polysciences) and 
300 µL of DMEM medium (serum-free) and incubated for 10 min at room temperature. 
When co-transfected with the pcDNA5/FRT plasmid into the Flp-In mammalian host 
cell line, the Flp recombinase expressed from pOG44 mediates the integration of the 
pcDNA5/FRT vector containing the gene of interest into the genome via Flp 
recombination target (FRT) sites. Clones resistant to hygromicine were collected and 
MOP-Cherry receptor expression was assessed by fluorescence microscopy.  
To induce expression of MOP-Cherry receptor, cells were treated with varying 
concentrations of doxycycline (Sigma) for different periods. The optimal expression of 
MOP-Cherry receptor was achieved after 24h of treatment with 0.01 µg of 
doxycycline/ml growth medium.  
 
Living Cell Epifluorescence Microscopy 
Cells expressing MOP receptors tagged with mCherry were grown on poly-D-lysine-
treated coverslips. Coverslips were placed into a microscope chamber containing 
physiological saline solution (130mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 20 
mM HEPES and 10 mM D-glucose, pH 7.4). Fluorescent images of the cells were 
acquired using a LEICA AF6500 Fluorescence Microscope equipped with a 63X 
(numerical aperture 1.3) oil inmersion lens. For internalization experiments in real time, 
drugs diluted in physiological saline solution were perfused into the microscope 
chamber, and pictures were taken at the different time points displayed in every picture.  
 
Cell lysates 
Flp-In MOP-Cherry cells were split into 6-well plates in DMEM medium supplemented 
with 5% fetal bovine serum, adding doxycycline either at different concentrations and at 
different time points.  Cells were placed on ice, DMEM medium was removed and cells 
were washed and lysed with RIPA 1x buffer (100mM HEPES, 300mM NaCl, 2% 
TritonX-100, 1% sodium deoxycholate, supplemented with 0.2% SDS, 250mM NaF, 
0.5M EDTA-Na2, 0.5M NaH2PO4, 5% ethylene glycol, pH 7,3) supplemented with a 
protease inhibitor cocktail tablet (Roche). Cellular extracts were then centrifugated for 
10 minutes at 14000 rpm, 4°C and the supernatant was recovered. Total protein 
concentrations were determined by the Bradford method using BSA as standard, and 
cell lysates were stored at -20°C until use. 
 
Western Blotting  
Samples were resolved by 4-12% Bis-Tris gel electrophoresis (Invitrogen) and 
transferred to nitrocellulose membranes. Blots were incubated in 5% non-fat milk-0.1% 
Tween 20/TBS-buffered solution at room temperature on a rotating shaker for 2h to 
block non-specific binding sites. The membrane was then incubated with an anti-µ 
antibody against the last 43 amino acid from C-terminus in blocking buffer at 4°C 
overnight. Blots were washed three times with TBS-0,1% Tween-20 buffer for 10 min 
each at room temperature and incubated with secondary antibody (anti-Goat peroxidase 
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conjugated IgG) (SIGMA) at 1:200000 in TBS-0,1% Tween-20 buffer for 1 h at room 
temperature. Blots were washed and visualized by ECL Prime Western Blotting 
Detection Reagent (Amersham). 
 
Cell Membrane Preparation 
Harvested pellets from Flp-In MOP Cherry cells kept at -80°C were thawed and 
resuspended in 10 mM Tris and 0.1 mM EDTA, pH 7.4 (Tris/EDTA buffer). Cells were 
homogenized by 25 passes of a glass-on-Teflon homogenizer. The resulting suspension 
was centrifuged at 1200g for 10 min to remove unbroken cells and nuclei. The 
supernatant was subsequently centrifuged at 20000 rpm for 1h in an Avanti centrifuge J-
30I (Beckman Coulter, Fullerton, CA). Resulting pellets were resuspended in 
Tris/EDTA buffer and passed 10 times through a 25-gauge needle. Protein 
concentration was assessed as above, and membranes were stored at -80°C until use. 
 
[3H]Diprenorphine Saturation Binding Assays.  
Cell membranes (14 µg of protein) were incubated with [3H]diprenorphine (0.02-2 nM 
in saturation assays) in a total volume of 1 ml of buffer (50 mM Tris-HCl, 1 mM 
EDTA, and 10 mM MgCl2, pH 7.4). Nonspecific binding was determined by the 
inclusion of 10-4 M naloxone. Binding was initiated by the addition of membranes, and 
tubes were incubated at 25°C for 60 min. The assay was terminated by rapid filtration 
using a cell harvester (Brandel Inc.) with three 5ml washes of ice-cold phosphate-
buffered saline (80 g NaCl, 2 g KCl, 14.4 g Na2HPO4, 2.4 g KH2PO4, pH 7.4). Filters 
were soaked in 3 ml of scintillation liquid, and radioactivity was determined in a 
scintillation counter (Beckman Coulter LS 6000IC). 
 
[35S]GTPγS Binding Assays.  
Cell membranes (14 µg of protein) were incubated in buffer (20 mM HEPES, 100 mM 
NaCl, and 4 mM MgCl2, pH 7.4) containing 10 µM GDP and DAMGO, as the agonist 
ligand, at different concentrations in dose response curves. For single point experiment 
cell membranes were incubated with DAMGO [10-5 M] and Naloxone [10-5 M], used as 
an inverse agonist ligand. All experiments were performed in triplicate. The reaction 
was initiated by the addition of cell membranes, and then membranes were incubated at 
30°C for 60 min in the presence of 0.1 nM [35S]GTPγS. The reaction was terminated by 
rapid filtration with a cell harvester (Brandel Inc.) and three 5 ml washes with ice-cold 
phosphate-buffered saline. Radioactivity was determined as described above. 
 
 
 
 
 
 
11 
 
Results 
We first proceeded to the amplification and ligation of a cDNA encoding for human 
MOP receptor to the sequence corresponding to mCherry fluorescent protein, in order to 
obtain a final single open reading frame chimeric protein by the fussion of mCherry to 
the carboxyl terminus of MOP receptor. This construct of 1920 bp was subcloned into 
pcDNA5/FRT/TO vector to be subsequently transfected into the 
tetracycline/doxycycline-inducible Flp-In locus of Flp-In T-REx HEK293 cells. After 
selection of positive clones by antibiotic resistance, we obtain a stable cell line 
expressing MOP-Cherry in an inducible manner (Fig. 2). 
 
 
The expression and cellular distribution of MOP-Cherry was assessed by means 
fluorescence microscopy in living cells. We performed a curve of doxycycline (DOX) 
concentrations and chose the optimal concentration (0,01 µg/ml) for our experimental 
model (Fig. 3C). Time course experiments of DOX treatment revealed, firstly, a MOP-
Cherry expression dependent of DOX induction (Fig. 3B), i.e., red fluorescence was 
undetectable in the absence of DOX beside a modest signal corresponding to cell 
autofluorescence (Fig. 3A). Conversely, DOX treatment resulted in the expression of 
MOP-Cherry receptors observed as specific red fluorescence signal distributed in 
punctuated and moving vesicles throughout cells (Suplemmentary material 1). The 
addition of DOX to the cell growth medium showed a time-dependent increase in MOP-
Cherry expression (Fig. 3B) that was accompanied by the augmentation of intracellular 
vesicles (Fig. 3A).   
 
 
 
Figure 2. Schematic representation of the stable cell line generation. cDNA encoding for 
human MOP receptor  was amplified and ligated to the sequence corresponding to mCherry 
fluorescent protein using enzymatic digestion. This construct of 1920 bp was subcloned into 
pcDNA5/FRT/TO vector to be transfected into Flp-In T-REx HEK293 cells to get its 
insertion in the inducible locus by homologous recombination.  
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Figure 3. Evaluation of MOP-Cherry receptor expression 
by DOX treatment in Flp-In HEK293 cells. A, Images 
were obtained after illuminating living cells with settings 
to detect mCherry (gray) and Hoechst 33342 (blue) 
fluorescence. Cells were treated with DOX (0.01 µg/ml) 
for different times displayed at the upper left corner of 
each picture. Addition of DOX resulted in a time-
dependent increase of MOP-Cherry receptor expression 
that was paralleled by the augmentation of intracellular 
vesicles. B, Western Blot (WB) analysis was performed 
with cell lysates from cells non treated (c), or treated with 
DOX for different periods. C, WB analysis performed 
with cell lysates treated with varying concentrations of 
doxycycline for 24 h.  
                                                                                                                                                      
B 
A 
C 
A 
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To further investigate on the nature of these trafficking vesicles, cells were treated for 
different periods with Concanavalin A, an endocytosis inhibitor (Fig. 4). Inhibition of 
vesicle formation was not apparent after 30 min of treatment (Supplementary material 
2), observing a total inhibition after 24h of endocytosis inhibitor presence 
(Supplementary material 3). 
 
In our experimental model MOP-Cherry receptor endocytosis is constitutive, i.e., it 
takes place in the absence of activating agonists. Moreover, it has been extensively 
described for many GPCRs constitutive activity in functional terms, which means that 
these receptors coupled to G proteins in the absence of any agonist.  
 
 
 
 
 
Figure 4. Effect of Concanavalin A on vesicle trafficking. Fluorescent microscopy images 
were obtained from living cells treated with DOX (0.01 µg/ml) for 24h. Concanavalin A 
(500 µg/ml) was added in parallel at the time point displayed in every picture 
14 
 
 
 
 
In order to test whether MOP-Cherry constitutive internalization is a G-protein coupling 
process, we treated cells with pertussis toxin (PTX), a drug capable of inhibiting the 
interaction between receptors and Gαi/o subunits, for 24h (Fig. 5A).  After PTX 
treatments we observe a significant decrease of both intracellular vesicle formation and 
receptor expression levels (Fig. 5A, and Suplemmenatry material 4). 
 
GPCRs constitutive activity might be inhibited as well by drugs known as inverse 
agonists. Thus, we treated cells with Naloxone (Nal) or Naltrexone (Nalt), to test their 
opioid inverse agonist properties (Cruz et al., 1996), at a saturating concentration [10-5 
M] for different periods (Fig. 5B and 5C). Any evident effect was observed, suggesting 
that in our experimental cell model neither naloxone nor naltrexone acts as inverse 
agonists. 
 
 
 
 
 
Figure 5. Effect of Pertussis toxin, Naloxone and Naltrexone on constitutive receptor 
endocytosis. Fluorescent microscopy images were obtained from living cells treated with 
DOX (0.01 μg/ml) for 24h to induce MOP Cherry receptor expression. A, cells treated with 
doxycycline for 24h (control) or with pertussis toxin (PTX 100ng/ml) for 24h. B, cells 
treated with Naloxone (Nal 10-5M) for 30 min and 24h. C, cells treated with Naltrexone 
(Nalt 10-5M) for 24h and 48h. 
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To get further insight in the cellular 
mechanisms involved in MOP-Cherry 
constitutive receptor internalization, we 
designed experiments to probe the role of 
dynamin in the endocytosis of MOP-Cherry 
receptors. On one hand, we treated cells with 
dynasore for 30min and 24h. Dynasore is a 
cell-permeable inhibitor of dynamin GTPase 
activity that facilitates the formation of 
coated pits in the process of endocytosis 
(Macia et al., 2006; Nankoe and Sever, 
2006). Dynasore treatment did not inhibit 
MOP-Cherry receptor internalization, since 
intracellular vesicles are observed in 
dynasore treated cells (Fig. 6B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Otherwise, cells were also transfected with a mixture containing a dominant-negative 
mutant N272 dynamin and GFP fluorescent protein (Fig. 6A) to monitor the effects of 
dynamin on membrane protein internalization. N272 dynamin is a dominant-negative 
dynamin mutant which lacks the complete GTP-binding domain (Werbonat et al., 
2000). As shown in Fig. 6A, cells transfected with the mixture also contains 
intracellular vesicles, suggesting that N272 dynamin did not affect MOP-Cherry 
internalization process.  
Figure 6. Effect of a dynamin dominant-
negative mutant transfection and dynasore on 
constitutive receptor endocytosis. A, cells were 
transfected with a mixture containing 
dominant-negative N272 dynamin and GFP 
fluorescent protein (0.1 μg/ml). Image were 
obtained after illuminating living cells 
previously treated with DOX (0.01 μg/ml) for 
24h, with settings to detect mCherry (gray) 
and GFP (green) fluorescence. B, cells were 
treated with dynasore (80 µM) for 30 min and 
24h. To induce MOP-Cherry receptor 
expression cells were treated with DOX (0.01 
   
 
A 
B 
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Next, we proceed to evaluate the pharmacological profile of MOP-Cherry receptors by 
[3H]diprenorphine and [35S]GTPγS binding assays. Saturation of specific 
[3H]diprenorphine binding sites in membranes from cells treated with DOX for different 
periods showed affinity values in agreement with the expected one for this antagonist:  
Kd= 0, 24 ± 0, 04 nM  after 24h of DOX treatment and Kd= 0, 27 ± 0, 03 nM after 96h 
of DOX treatment. Regarding receptor expression levels, we observed a significant 
increase in receptor expression in samples from those cells treated with DOX for longer 
periods compared to membranes from cells untreated (Fig 7 and Table 2). Pertussis 
toxin treatment significantly decreases MOP-Cherry receptor expression (Fig 7 and 
table 2), result that was also corroborated by western blot assays (Fig. 8C). 
Pharmacological parameters are displayed in Table 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Pharmacological parameters of [3H]diprenorphine saturation binding assays performed 
with membranes from cells treated with DOX for 24h, with DOX for 96h, or with DOX plus 
pertussis toxin for 24h. Parentheses indicate number of independent experiments performed. 
Values are presented as mean ± S.E.M. The values in parentheses represent n. 
 
 
 
 
 
 
 
 
 Bmax (fmol/mg) Kd 
24h DOX  2229,5 ± 514,85 (3) 0,2467 ± 0,0404 (3) 
96h DOX  3555,1 ± 727,17 (3) 0,2767 ± 0,0306 (3) 
24h PTX  898,05 (1) 0,44 (1) 
Figure 7. Specific [3H]diprenorphine saturation binding assays. A, performed with 
membranes from cells non treated (green), treated with DOX for 24 hours (red), with DOX 
for 96 hours (blue) B, or with DOX plus pertussis toxin for 24 hours (black).  
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[35S]GTPγS binding experiments were performed in membranes from cells treated with 
DOX for different times, using DAMGO as agonist at different concentrations (Fig. 
8A), in order to stimulate the specific incorporation of [35S]GTPγS in membranes. 
Despite membranes obtained from cells treated with DOX for 24h or 96h have different 
baseline values; we obtained similar curves when plotted as fold over basal (Fig. 8A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. [35S]GTPγS binding assays. A, membranes obtained from cells treated with 
doxycycline (0.01 µg/ml) at different times to induce MOP-Cherry receptor expression were 
incubated with an agonist (DAMGO) at different concentrations. Results are expressed in 
cpm and in fold over basal. B, membranes obtained from cells non treated (-DOX), treated 
with doxycycline for 96h (DOX 96h) or with doxycycline plus pertussis toxin for 24h 
(PTX) were incubated with DAMGO (10-5M) or an antagonist/inverse agonist (naloxone 10-
4M). C, Western Blott analysis performed with membranes used in [35S]GTPγS assays from 
cells non treated (c), treated with DOX for 24 hours (24h), with DOX for 96 hours (96h) or 
with DOX plus pertussis toxin for 24 hours (PTX). 
 
C 
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As previously shown by microscopy experiments and radioligand bindings, MOP-
Cherry receptor expression is undetectable in the absence of DOX, therefore the extent 
of [35S]GTPγS binding in response to DAMGO  was greater in the treated than in the 
untreated cells (Fig. 8B). DAMGO stimulated the specific incorporation of [35S]GTPγS 
in a dose-dependent manner (Fig. 8A) whereas naloxone did not show any effect (Fig. 
8B). Membranes from cells treated with pertussis toxin plus DOX for 24h were devoid 
of interaction between receptors and Gαi/o subunits (Fig. 8B). The pharmacological 
parameters of [35S]GTPγS experiments are shown in table 3. 
 
 
Table 3. Pharmacological parameters of [35S]GTPγS binding assays performed with 
membranes from cells treated with DOX for 24 hours or with DOX for 96 hours. Parentheses 
indicate number of independent experiments performed. Values are presented as mean ± S.E.M. 
The values in parentheses represent n. 
 
 
Sample pEC50 
24h DOX 8,240 ± 0,10 (3) 
96h DOX 8,667 ± 0,02 (3) 
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Discussion 
 
G protein-coupled receptors are the most common cellular targets for drugs used in 
clinic (Rosenbaun et al., 2009). Of the four main opioid receptor subtypes, µ-opioid 
receptors are of the greatest clinical importance, because they mediate the physiological 
actions of clinically used opioid alkaloid drugs such as morphine. 
In this study, we have generated a permanent cell line heterologously expressing MOP-
Cherry receptors in an inducible manner to conduct molecular pharmacological studies. 
This experimental system provides MOP-Cherry expression by using doxycycline as an 
ON/OFF agent allowing the use of the same host cells as negative control when MOP-
Cherry receptor is not induced to express. In this particular expression model, MOP-
Cherry receptor distributes both in the cell membrane and as trafficking vesicles. 
Addition of DOX resulted in a concentration- and time-dependent increase of MOP-
Cherry receptor expression that was paralleled by the augmentation of intracellular 
vesicles. 
The origin of these vesicles corresponds to a constitutive endocytosis process since 
Concanavalin A treatment cause the complete inhibition of vesicle formation. ConA 
binds terminal sugar residues resulting in the agglutination of cell surface receptors and 
has been used to block GPCR internalization (Luttrell et al., 1997). As revealed in our 
results, inhibition of vesicle formation was observed after 4h of ConA treatment. There 
is no evident effect of vesicle formation inhibition after the first 30 min of ConA 
treatment; probably because that is due to the previously presence of vesicles before 
starting treatment. 
We decided to investigate MOP-Cherry receptor endocytosis mechanisms and designed 
experiments to inhibit dynamin-dependent pathways. In the present studies both 
dynasore and dominant-negative mutant N272 dynamin were unable to inhibit MOP-
Cherry receptor internalization, suggesting then that MOP-Cherry receptor 
internalization is a clathrin-independent endocytosis.  
As observed in fluorescent microscopy images, pertussis toxin treatment shows a 
significant decrease of both intracellular vesicle formation and receptor expression 
level, suggesting that the constitutive MOP-Cherry receptor endocytosis is a G-protein 
coupled dependent process. This result was also corroborate by western blot assays, 
[35S]GTPγS and [3H]diprenorphine binding experiments, since membranes from cells 
treated with pertussis toxin for 24h were devoid of interaction between receptors and 
Gαi/o subunits and showed a significant decrease in receptor expression level. 
Constitutive activity has been previously demonstrated for MOP receptor (Burford et 
al., 2000) and could be defined as the coupling of receptors to G proteins in absence of 
activating agonists. There are compounds that stabilize poorly coupled state of MOP 
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receptors and consequently can inhibit the constitutive activity. These compounds are 
known as inverse agonists. The degree to which these ligands inhibit the basal level of 
the output being measured is considered to reflect the amount of constitutive activity 
present in the system. However, intrinsic eficacy is not a fixed characteristic of 
receptors but it appears to depend on the context of the cells, the state of the receptor, 
and experimental conditions (Fathy et al. 1999; Yang and Lanier 1999). 
 
Naloxone and naltrexone are compounds which have exhibited properties of inverse 
agonist at MOP receptor (Wang et al. 1994; Burford et al., 2000).  In our experimental 
model, cells treated with naltrexone or naloxone did not show any evident effect on 
either constitutive endocytosis or constitutive activity of MOP-Cherry receptors, as 
observed in fluorescent microscopy images as well as in [35S]GTPγS binding assays. In 
relation to receptor expression levels any of both compounds affected the number of 
MOP-Cherry receptors as observed in PTX treatment. Overall and taking together, these 
results suggest that in this experimental cell model both naloxone and naltrexone do not 
act as inverse agonists. 
 
There have been previously described two cases of constitutive endocytosis of MOP 
receptors in the literature. Macé and co-workers established that p38 MAPKs play a key 
role in the modulation of MOP endocytosis. By investigating the molecular mechanisms 
that underlie MOP endocytosis, they uncovered an unexpected functional connection 
between p38 MAPK activity and the endocytic machinery regulated by the small 
GTPase Rab5. They showed that p38 MAPKs can phosphorylate EEA1, one of the best-
characterized Rab5 effectors, and Rabenosyn-5 on Thr-1392 and Ser-215, and that both 
phosphorylation sites are located within the FYVE finger, which plays an essential role 
in the recruitment of the proteins to the early endosome membrane by a clathrin-
dependent process. Interestingly and supporting their results, a published genome-wide 
screen uncovered a wider role of protein kinases in the regulation of endocytosis 
(Pelkmans et al, 2005). They demonstrate that p38 MAPK activation is required for 
MOP endocytosis in HEK293 cells and sufficient to trigger its constitutive 
internalization in the absence of agonist (Macé et al., 2005). 
 
Other research published by Koch and collaborators (Koch et al., 2006) showed that 
MOP receptor is associated with the phospholipase D2 (PLD2), a phospholipid-specific 
phosphodiesterase located in the plasma membrane. PLD is a widely distributed 
enzyme, its principle substrate is phosphatidylcholine and its product, phosphatidic acid, 
is believed to have many different functions in signal transduction, vesicle formation 
and cytoskeletal dynamics (Liscovitch and Cantley 1995). They demonstrate in human 
embryonic kidney 293 cells, that the mouse C-terminal splice variant of the µ-opioid 
receptor (MOR1D) exhibited robust endocytosis in response to both DAMGO and 
morphine treatment. Moreover, they report that MOR1D also mediates an agonist-
independent (constitutive) PLD2-activation facilitating agonist-induced and constitutive 
receptor endocytosis. It has been previously described that PLD2 might be involved in 
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vesicle formation from the plasma membrane (Colley et al. 1997). Furthermore, PLD-
activity has been shown to be regulated by a number of GPCRs including MOP receptor 
(Koch et al. 2003). This group provides evidence for an essential role of PLD2 in the 
agonist-induced and constitutive endocytosis of the µ-opioid receptor splice variant 
MOR1D. They presume that the ARF6 protein, which has been demonstrated to 
selectively activate PLD2 in vivo (Hiroyama and Exton 2005), might be involved in the 
GPCR-mediated PLD2 activation. This assumption was supported by findings that 
ARF6 protein plays an essential role in the endocytosis regulation of GPCRs 
sequestered via the clathrin-coated pathway (Claing 2004; Houndolo et al. 2005). 
Therefore they suggest that is possible that the GPCR mediated PLD2 stimulation may 
involve a direct interaction of receptors with ARF protein. Furthermore, it has been 
elucidated that β-arrestins also function as endocytic adapters, linking receptors to the 
clathrin-coated pit machinery (Shenoy and Lefkowitz 2003; Claing 2004) and that the 
interaction of β-arrestins with endocytotic elements including clathrin and the adapter 
protein 2 (AP-2) are important for induction of clathrin-dependent GPCR endocytosis 
(Laporte et al. 2002). Thus they concluded that receptor endocytosis might be regulated 
by both GPCR binding to β-arrestin and GPCR-mediated PLD2 activation resulting in 
the subsequent recruitment and/or interaction with components of the AP-2 complex. In 
fact, this study revealed that PLD2 activity is essential for both constitutive and agonist 
dependent MOR1D receptor endocytosis. They concluded that agonist-independent 
PLD2 activation provides an important alternative mechanism to β-arrestin for the 
regulation of constitutive endocytosis of GPCRs. 
 
Our results show that MOP-Cherry receptor internalization is a clathrin-independent 
endocytosis process, since the inhibition of dynamin through different experiments does 
not promote the inhibition of vesicle formation. Recently, we have made considerable 
use of Flp-In T-Rex HEK293 cells in order to express and study different GPCRs, and 
we have not seen before constitutive internalization of other forms of MOP receptors 
heterologously expressed in this system (Lopez-Gimenez et al., 2008), excluding 
therefore an artifactual effect of the host cells on this constitutive endocytosis. However 
further investigations to determine the implication of phospholipase D2 and p38MAPKs 
on constitutive MOP-Cherry endocytosis our required. 
The pharmacological characterization shows that the expressed MOP-Cherry construct 
is functional. The highly MOP-selective enkephalin analog DAMGO stimulated binding 
of [35S]GTPγS in membranes from cells expressing MOP-Cherry receptors in a 
concentration-dependent manner. As suggested by the higher levels of MOP-Cherry 
receptor expression in cells treated with DOX for 96h, previously observed in 
microscopy images,  the extent of  [35S]GTPγS in response to DAMGO was greater in 
cells treated with DOX for longer periods, an effect achieved without a significant 
alteration in the potency of DAMGO. These effects of DAMGO were lacking in 
pertussis toxin-treated cells, indicating that [35S]GTPγS binding via MOP-Cherry was to 
pertussis toxin-sensitive members of the Gαi subgroup. Moreover, specific 
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[3H]diprenorphine binding experiments showed affinity values (Kd) in agreement with 
the previously described for this antagonist (Raynor et al., 1995) and corroborate the 
significant increase in receptor expression levels observed in samples from cells treated 
with DOX for 96h by fluorescent microscopy and western blot experiments. 
Further investigations to determine whether MOP-Cherry receptor constitutive 
endocytosis concurs with receptor functional constitutive activity will be conducted. If 
this is the case, this experimental model would represent a model of choice to 
pharmacologically characterize potential inverse agonist compounds.     
Conclusions 
 We have generated a permanent cell line heterologously expressing MOP-
Cherry receptors in an inducible manner. This experimental system provides 
MOP-Cherry receptor expression by using doxycycline as an ON/OFF agent. 
 The expression level of our gene of interest might be regulated depending on the 
DOX dose and period of treatment.  
 In this particular expression model, MOP-Cherry receptor distributes in 
trafficking vesicles as a result of constitutive endocytosis that is a G-protein 
coupling dependent process. 
 Further investigations to determine whether MOP-Cherry constitutive 
endocytosis concurs with receptor functional constitutive activity will be 
conducted. If this is the case, this experimental model would represent a model 
of choice to pharmacologically characterize potential inverse agonist 
compounds. 
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